Molecular proximity orchestrates biological function, and blocking existing proximities is an
established therapeutic strategy. By contrast, strengthening or creating neoproximity with …

Protein–protein interactions (PPIs) govern all biological processes. Some small molecules
modulate PPIs through induced protein proximity. In particular, molecular glue degraders …

With advances in chemically induced proximity technologies, heterobifunctional modalities
such as proteolysis targeting chimeras (PROTACs) have been successfully advanced to …

Living systems use proximity to regulate biochemical processes. Inspired by this
phenomenon, bifunctional modalities that induce proximity have been developed to redirect …

The cancer genomics revolution has served up a plethora of promising and challenging
targets for the drug discovery community. The field of targeted protein degradation (TPD) …

Targeted protein degradation refers to the use of small molecules to induce the selective
degradation of proteins. In its most common form, this degradation is achieved through …

Small molecules that induce protein–protein associations represent powerful tools to
modulate cell circuitry. We sought to develop a platform for the direct discovery of …

In recent years, with the successful development of proteolysis-targeting chimeric molecules
(PROTACs), the potential of heterobifunctional molecules to contribute to reenvisioning drug …

Only around 20% of the human proteome is considered to be druggable with small-molecule
antagonists. This leaves some of the most compelling therapeutic targets outside the reach …

A paradigm shift in drug development is the discovery of small molecules that harness the
ubiquitin-proteasomal pathway to eliminate pathogenic proteins. Here we provide a modality …